422 related articles for article (PubMed ID: 36453898)
1. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
[TBL] [Abstract][Full Text] [Related]
5. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa Promotes Persistence of Stenotrophomonas maltophilia via Increased Adherence to Depolarized Respiratory Epithelium.
McDaniel MS; Lindgren NR; Billiot CE; Valladares KN; Sumpter NA; Swords WE
Microbiol Spectr; 2023 Feb; 11(1):e0384622. PubMed ID: 36472421
[TBL] [Abstract][Full Text] [Related]
7. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
8. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
[TBL] [Abstract][Full Text] [Related]
9. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA
J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523
[TBL] [Abstract][Full Text] [Related]
10. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
11. Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients.
Mooney L; Kerr KG; Denton M
Int J Antimicrob Agents; 2001 Jan; 17(1):63-6. PubMed ID: 11137651
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
[TBL] [Abstract][Full Text] [Related]
13. Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.
Quinn AM; Bottery MJ; Thompson H; Friman VP
ISME J; 2022 Oct; 16(10):2433-2447. PubMed ID: 35859161
[TBL] [Abstract][Full Text] [Related]
14. Inter-species interactions alter antibiotic efficacy in bacterial communities.
Bottery MJ; Matthews JL; Wood AJ; Johansen HK; Pitchford JW; Friman VP
ISME J; 2022 Mar; 16(3):812-821. PubMed ID: 34628478
[TBL] [Abstract][Full Text] [Related]
15. Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.
Jabalameli F; Emaneini M; Beigverdi R; Halimi S; Siroosi M
Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):61. PubMed ID: 37475017
[TBL] [Abstract][Full Text] [Related]
16. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
McCaughey G; Diamond P; Elborn JS; McKevitt M; Tunney MM
PLoS One; 2013; 8(7):e69763. PubMed ID: 23936095
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
18. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
19. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
20. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
Ratjen A; Yau Y; Wettlaufer J; Matukas L; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2015 Jan; 59(1):711-3. PubMed ID: 25348526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
